SoftWave Tissue Regeneration Technologies’s extracorporeal shock wave device – OrthGold 100, received FDA clearance for the indications of a temporary increase in local blood circulation, relief of minor aches and pains, and activation of connective tissue.
John Warlick, CEO, SoftWave TRT, said: “This revolutionizes the way pain is treated in a therapeutic setting. With a company focus on innovation, adding more patents, and contributing to our pipeline of future clearances and approvals, we believe SoftWave TRT is positioned to offer the best shock wave technology and be the leader in this growing segment of medical technology.”
The OrthoGold 100 can provide relief from tendonitis, bursitis, arthritis, and other common conditions. SoftWave TRT’s patented technology uses an unfocused extracorporeal shock wave (uESWT) to promote physical and biological response to improve healing. It positively influences the activity of immune cells, has an anti-inflammatory potential, including the stimulation of mesenchymal stem cells and the release of factors relevant to regeneration and healing. In addition, the shock wave intervenes directly in the signal transmission of pain and has both short-term and long-term analgesic effects. One of the advantages of SoftWave Therapy is relieving acute pain in the short term and providing long-term relief by dissolving the actual cause through regeneration and healing. It is a non-invasive procedure and requires no anesthesia or numbing agents.